8-K: Sonnet BioTherapeutics Reports Q2 2024 Financial Results and Provides Business Update

Sonnet BioTherapeutics announced its financial results for the second quarter of fiscal year 2024, highlighting progress in clinical trials and cost-saving measures.

Summary

• Sonnet BioTherapeutics released its financial results for the three and six months ended March 31, 2024, along with a business update.
• The company reported $3.8 million in cash on hand and no debt as of March 31, 2024.
• Research and development expenses decreased to $2.2 million for the quarter, down from $3.8 million in the same period last year, due to cost-saving initiatives.
• General and administrative expenses also decreased to $1.7 million from $1.9 million year-over-year.
• Sonnet generated $4.3 million in net proceeds from the sale of net operating losses through the New Jersey Technology Business Tax Certificate Transfer Program.
• The company anticipates its current cash will fund operations into July 2024, with potential for further extensions into August through additional cost reductions.
• Sonnet has entered into an equity facility with Chardan to raise additional capital.
• The company is focusing on its SON-1010 and SON-080 programs, with the SON-1010 program showing positive safety and tolerability data.
• The SON-080 program has been placed on hold for CIPN, but will be leveraged for a new Phase 2 study in Diabetic Peripheral Neuropathy (DPN).

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the limited cash runway, the need for a capital raise, and the pause in development of SON-080 for CIPN. However, there are some positives such as the cost reductions and positive early data for SON-1010.

Positives

• The company successfully reduced research and development expenses by $1.6 million year-over-year.
• Sonnet generated $4.3 million in net proceeds from the sale of net operating losses.
• SON-1010 showed favorable safety and tolerability in healthy volunteers.
• Early safety data for SON-080 in CIPN was positive, meeting the study's initial objective.
• The company has initiated partnering outreach for SON-080, aiming for commercialization.
• The company has entered into an equity facility with Chardan to raise additional capital.

Negatives

• The company's cash on hand is only projected to last into July 2024, with a potential extension to August through further cost reductions.
• Development of SON-080 for CIPN has been placed on hold.
• The company has suspended antiviral development related to SON-1010 and programs related to SON-080 and SON-1210 while seeking partnering opportunities.

Risks

• The company's limited cash runway poses a risk to its operations beyond July or August 2024.
• The need to secure additional funding through an equity facility with Chardan indicates potential dilution for existing shareholders.
• The suspension of certain development programs highlights the company's financial constraints and need to prioritize projects.
• The reliance on partnering for SON-080 introduces uncertainty regarding its future development and commercialization.

Future Outlook

The company projects its current cash will sustain operations into July 2024, with potential for additional expense reductions to extend into August. They are also seeking additional capital through an equity facility with Chardan.

Management Comments

• We are very excited about the progress we made during the first calendar quarter of this year with the SON-1010 and SON-080 programs, where the foundations for the compounds safety profiles were further strengthened, said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer.
• We will look to continue to build on the supporting data for SON-1010 with the forthcoming look at the PDL-1 combination study in platinum-resistant ovarian cancer during the current quarter.
• We ended another quarter with solid pipeline progress and continue to work to manage our operating expense infrastructure accordingly.
• We recently entered into an equity facility with Chardan to raise additional capital said Jay Cross, CFO.

Industry Context

This announcement reflects the challenges faced by many biotech companies in managing cash flow while advancing clinical programs. The focus on cost-saving measures and strategic partnering is a common approach in the current market environment. The company's focus on oncology and innovative biologic drugs aligns with broader industry trends in targeted therapies.

Comparison to Industry Standards

• Sonnet's cash position of $3.8 million is relatively low compared to other publicly traded biotech companies at a similar stage of development, such as those with multiple Phase 2 assets.
• The reduction in R&D expenses is a positive sign of cost management, but it is important to compare this to the burn rate of similar companies to assess its sustainability.
• The $4.3 million generated from the sale of net operating losses is a non-recurring event and should not be considered a sustainable source of funding.
• The company's decision to pause development of SON-080 for CIPN and pivot to DPN is a strategic move that reflects the need to focus on areas with higher commercial potential, similar to other companies that have pivoted their clinical programs.
• The partnering outreach for SON-080 is a common strategy for biotech companies to share the risk and cost of development, similar to other companies that have partnered with larger pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience dilution due to the equity facility with Chardan.
• Employees may be affected by the cost-saving initiatives and program suspensions.
• Patients may benefit from the continued development of SON-1010 and the new Phase 2 study in DPN.
• Potential partners may be interested in the SON-080 program.

Next Steps

• The company will continue to build on the supporting data for SON-1010 with the forthcoming look at the PDL-1 combination study in platinum-resistant ovarian cancer.
• Sonnet plans to initiate a new Phase 2 study in Diabetic Peripheral Neuropathy (DPN) using the data from the SON-080 CIPN study.
• The company will continue partnering outreach for SON-080 to move towards commercialization.
• Sonnet will seek additional capital through an equity facility with Chardan.

Key Dates

Keywords

biopharmaceutical, clinical trials, oncology, FHAB, SON-1010, SON-080, Interleukin 12, Interleukin 6, CIPN, DPN, research and development, financial results, cost savings